Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tosposertib + Pembrolizumab in Advanced Solid Tumors
NCT05784688Phase 2Recruiting
- Sponsor
- TiumBio Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tosposertib in solid tumor, biliary tract cancer (BTC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), sponsored by TiumBio Co., Ltd.. Started Mar 2023; status: recruiting.
02
Drugs
tosposertib
03
Conditions
solid tumorbiliary tract cancer (BTC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05784688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784688.